Online inquiry

IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8288MR)

This product GTTS-WQ8288MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8288MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10206MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ1851MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ7908MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ6438MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ1568MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ113MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ8878MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ11054MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW